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Abstract
Purpose Dolutegravir (DTG), an unboosted HIV integrase
inhibitor (INI), is metabolized by UGT1A1 and to a minor
extent by CYP3A. Renal elimination of unchanged DTG is
very low (< 1 %). As renal impairment may affect pharmaco-
kinetics (PK), even for drugs primarily metabolized or secret-
ed in bile, this study investigated the effect of renal impair-
ment on the PK of DTG.
Methods This was an open-label, single-dose study of oral
DTG 50 mg administered to subjects with severe renal im-
pairment (creatinine clearance [CLcr] <30 mL/min; not on
dialysis) and to healthy controls (CLcr >90 mL/min) matched
for gender, age and body mass index (8 subjects per group).
Serial PK samples were collected up to 72 h post-dose for
determination of DTG and DTG-glucuronide (DTG-Gluc)
concentrations in plasma. DTG unbound fraction in plasma
was determined at 3 and 24 h. PK parameters were determined
by non-compartmental methods and compared between
groups by analysis of covariance.
Results DTG was well tolerated with a low incidence of
Grade 1 adverse events. DTG PK parameters showed signif-
icant overlap between groups. DTGmean exposure was lower
in subjects with severe renal impairment compared to healthy,
matched subjects: AUC(0-∞) and Cmax were 40 % and 23 %
lower, while mean DTG-Gluc was increased. Renal impair-
ment did not affect DTG fraction unbound in plasma.
Conclusions The modest reductions in mean PK exposures
for DTG and increases for DTG-Gluc in the severe renal
impairment group are not considered clinically significant.
DTG does not require dose adjustment in patients with renal
impairment.
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impairment . Protein binding
Introduction
Dolutegravir (DTG) is an investigational integrase inhibitor
(INI) for treatment of HIV infection which has demonstrated
safety and efficacy in Phase 3 trials [1–3]. Its unique resistance
profile supports its antiviral activity in patients who have
previously failed treatment with the INI raltegravir [4].
The pharmacokinetic (PK) profile of DTG is characterized
by a long half-life supporting once-daily dosing in INI-naïve
subjects, no requirement for boosting with ritonavir, and a
well-characterized PK/pharmacodynamic relationship dem-
onstrated in short-term monotherapy [5, 6]. DTG is primarily
metabolized via glucuronidation by UGT1A1 in the liver, and
to a minor extent by CYP3A. It is greater than 99 % bound to
plasma proteins [7]. DTG is the predominant circulating com-
pound in plasma (>97 % of drug-related components) and
renal elimination of unchanged drug is extremely low (<1 %
of the dose) [8]. Approximately 53% of a dose is recovered as
DTG in feces and approximately 31 % is excreted in the urine
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primarily as DTG-glucuronide (DTG-Gluc) and other minor
metabolites [8].
Severe renal impairment can impact the PK of drugs which
are primarily metabolized or secreted in bile [9]. Current
regulatory guidance recommends evaluation of drug PK in
subjects with renal impairment, even for drugs that are pri-
marily metabolized [10]. Accordingly, this study investigated
if renal impairment significantly affects the PK of DTG.
Methods
Study design and participants
This was a single-center, Phase I, single-dose, open-label
study in human subjects with severely impaired renal function
who are not on renal replacement therapy, in comparison to a
matched group of healthy subjects with normal renal function.
Severe renal impairment was defined as a creatinine clearance
(CLcr) <30 mL/min based on 24-hour urine creatinine clear-
ance within 30 days of the treatment period. Healthy subjects
were required to have CLcr >90 mL/min based on 24-hour
urine creatinine clearance within 30 days of the treatment
period and were matched to severe renal impaired subjects
for gender, age (±5 years) and body mass index (±25 %). As
race/ethnicity has not been shown to affect DTG pharmaco-
kinetics, this was not used as a factor for matching [11]. A
sample size of eight subjects per group was chosen based on
regulatory guidance for studies in renal impairment [10].
HIV-seronegative male and female participants between 18
to 70 years of age and with a body weight ≥50 kg and BMI in
the range of 19 to 38 kg/m2 were eligible for enrollment.
Subjects with renal impairment were enrolled if they met the
CLcr inclusion criteria and had laboratory test results that
were considered clinically stable by the principal investigator
(PI). Renal impairment subjects were excluded for recent
hepatitis B infection, a positive HIV antibody and pre-
existing conditions (other than renal impairment) that might
interfere with normal gastrointestinal anatomy or motility and/
or those that could interfere with absorption, metabolism, or
excretion of the study drug. All subjects could not have
consumed red wine, Seville oranges or grapefruit products
within 7 days prior to the dose of study medication until the
collection of the last PK sample, but renally impaired subjects
were permitted to use concomitant medications that were
considered medically necessary by the PI and did not have
the potential to affect DTG exposure, as determined by effects
on DTG metabolic pathways. Antacids, vitamins, and supple-
ments were held on the day of dosing.
Healthy participants were determined to be eligible for
inclusion based on physical exam, medical history, and labo-
ratory evaluation. They could not receive any prescription or
nonprescription drugs or consume red wine, Seville oranges
or grapefruit products within 7 days prior to the dose of study
medication until the collection of the last PK sample. Further-
more, exclusion criteria for healthy participants included a
positive pre-study drug screen for drugs of abuse.
Subjects received a single 50 mg tablet of DTG in the
morning in a fasted state and were housed in the study center
until collection of the last PK sample. Blood samples for
determination of total DTG and DTG-Gluc plasma concen-
trations were collected pre-dose and at 1, 2, 3, 4, 5, 6, 8, 12,
24, 48, and 72 h post-dose. Additional plasma samples were
collected at 3 and 24 h post-dose for measurement of unbound
plasma concentrations of DTG. Safety was assessed through-
out the study by clinical and laboratory evaluations and at
follow-up 7 to 10 days after administration of the DTG dose.
Written informed consent was obtained from all partici-
pants prior to conduct of any study-specific procedures and
the protocol was approved by the IRB (Western Institutional
Review Boards, Olympia, WA).
Bioanalytical methods
DTG (MW=419.38) and DTG-Gluc (MW=594.51) concen-
trations in plasma were determined by validated, high perfor-
mance liquid chromatographic/tandem mass spectrometric
methods following extraction with acetonitrile. Determination
of unbound DTG concentration was conducted by equilibrium
dialysis. Details of the analytical method and assay perfor-
mance are provided in the supplementary document.
Pharmacokinetic analysis
Analysis of the DTG and DTG-Gluc concentration-time data
was performed by noncompartmental PK methods
(WinNonlin® Professional Edition 5.2; Pharsight Corpora-
tion, Mountain View, CA). Plasma DTG PK parameters cal-
culated included area under the plasma concentration–time
curve from time zero to infinity (AUC(0-∞)), area under the
plasma concentration–time curve from time zero to the last
quantifiable time point [AUC(0-t)], maximum observed plas-
ma concentration (Cmax), time to Cmax (tmax), concentration
at 24 h after dosing (C24), apparent oral clearance (CL/F),
apparent volume of distribution (Vz/F), and terminal elimina-
tion phase half-life (t1/2). The same PK parameters were
determined for DTG-Gluc except for CL/F, Vz/F and C24.
Additionally, molar ratios of DTG-Gluc/DTG were deter-
mined for AUC(0-t) and Cmax, as was the DTG-Gluc/DTG
t1/2 ratio.
Unbound fraction (fu) was calculated using the total and
unbound plasma concentration of DTG data generated at 3
and 24 h post-dose for both healthy and renal impairment
subjects using the following formula: fu=C(unbound)/C(to-
tal), where C(unbound) and C(total) are the unbound and total
concentration of DTG in plasma, respectively.
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Statistical analysis
Statistical analysis was performed on the log-transformed PK
parameters, except tmax and tlag. Analysis of covariance
(ANCOVA) was performed using the SAS system (Version
9.1; SAS Institute Inc, Cary, NC) with gender as a fixed effect
and with age and BMI as continuous covariates. For each log-
transformed PK parameter, the point estimate and its associ-
ated 90 % confidence interval (CI) was constructed for the
difference between subjects with renal impairment (test) and
matched healthy controls (reference). The difference in PK
parameter and its 90 % CI was then exponentiated to obtain
the ratio of geometric least squares means and its 90 % CI on
the original scale. For DTG-Gluc/DTG ratios, Hodges–
Lehmann estimates of difference and 90 % CI were deter-
mined. Pearson correlation coefficients between creatinine
clearance and DTG parameters and creatinine clearance and
DTG-Gluc PK parameters were provided.
Results
Study population
Sixteen subjects (8 renal impairment; 8 healthy) were enrolled
and completed all study assessments. Summary demographics
are provided in Table 1. Groups were similar in age, gender
and BMI given the matching criteria. There were 5 African-
Americans and 3 Caucasians in the renal impairment group
and 2 African-Americans and 6 Caucasians in the healthy
subject group. Concomitant medications in the renal impair-
ment group were most commonly administered for treatment
of hypertension, diabetes, and lipid disorders.
Pharmacokinetics
Mean concentration-time profiles of DTG and DTG-Gluc in
subjects with and without renal impairment are shown in
Fig. 1. Summary DTG pharmacokinetic parameter estimates
are provided in Table 2. Subjects with severe renal impairment
had an average 40% lower plasma DTGAUC(0-∞) and 23%
lower Cmax than subjects with normal renal function. This
was accompanied by a mean elimination half-life that was
shorter by 18 % in the subjects with renal impairment com-
pared to controls (12.7 vs 15.4 h, respectively). There was
considerable overlap in the plasmaDTG PK parameters and in
the direction of the change between renally impaired and
healthy subjects. When compared to their matched controls,
6/8 healthy subjects had a higher AUC while 2/8 renally
impaired subjects had a higher AUC. Values for AUC(0-∞)
ranged from 13.6 to 46.7 μg*h/ml in renal impairment sub-
jects and from 14.1 to 60.9 μg*h/ml in matched healthy
subjects. For Cmax, 4/8 healthy subjects had a higher value
while 3/8 renally-impaired subjects had a higher value and one
matched pair demonstrated similar a Cmax (1.8 vs 1.9 μg/mL).
Cmax ranged from 0.79 to 2.1 μg/ml in renal impairment
subjects and from 0.82 to 3.2 μg/ml in healthy subjects. Vari-
ability in DTG PK parameters was similar between the two
groups (Table 2). No significant correlation was observed be-
tween creatinine clearance and DTG PK parameters (p >0.1).
The unbound fraction (fu) was similar between the severe
renal impairment and normal renal function groups, but the
GLS mean unbound plasma DTG concentrations were 14 %
lower at the 3-hour time point and 49 % lower at the 24-hour
time point in the renal impaired subjects (Table 2). Variability
in DTG unbound fraction was higher in subjects with severe
renal impairment. There was no apparent correlation between
DTG unbound fraction and DTG total concentration in plas-
ma, suggesting that protein binding is independent of DTG
concentration over the range of concentrations observed in
this study.
Plasma DTG-Gluc AUC(0-∞) and Cmax in the subjects
with severe renal impairment were approximately fourfold
and threefold higher than those in the healthy subjects (Table 3).
The median molar DTG-Gluc-to-DTG AUC ratio increased
from 0.011 in healthy subjects to 0.053 in subjects with severe
Table 1 Subject demographics
BMI body mass index, SD stan-
dard deviation
Demographics Severe Renal Impairment Healthy Matched Controls
Age, mean (SD), y 56.8 (7.42) 56.1 (8.32)
Sex, n (%)
Female 3 (38) 3 (38)
Male 5 (63) 5 (63)
BMI, mean (SD), kg/m2 31.34 (6.23) 29.36 (4.08)
Height, mean (SD), cm 174.19 (10.09) 171.21 (9.06)
Weight, mean (SD), kg 94.48 (17.09) 86.59 (17.05)
Race, n (%)
African American/African heritage 5 (63) 2 (25)
White, White/Caucasian/European heritage 3 (38) 6 (75)
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renal impairment, and the median molar DTG-Gluc-to-DTG
Cmax ratio increased from 0.015 in healthy subjects to 0.045 in
subjects with severe renal impairment. The molar DTG-Gluc-
to-DTG ratio of AUC and Cmax expressed as a percentage was
1–5.5 %, indicating that DTG is the predominant species in
plasma, even in renal impairment. AUC(0-t) and Cmax ratios
of DTG-Gluc to DTGwere higher in subjects with severe renal
impairment than healthy matched subjects. The t1/2 ratio of
DTG-Gluc to DTG is close to 1 in both groups of subjects,
indicating that the terminal t1/2 of DTG-Gluc is similar to that
of DTG, and that the formation-rate-limited kinetics for DTG-
Gluc was not altered by severe renal impairment. There was a
statistically significant negative correlation between creatinine
clearance and DTG-Gluc PK parameters including AUC(0-t),
AUC(0-∞) and Cmax (p <0.05, correlation coefficients range -
0.54 to -0.60), but not for the t1/2 of DTG-Gluc (p >0.05,
correlation coefficient = −0.07).
Safety
DTG was well tolerated in both treatment groups. No deaths
or serious adverse events occurred during this study. No
subjects were withdrawn from the study due to adverse events
(AEs) and all AEs were mild (Grade 1) in intensity. One
subject with severe renal impairment experienced an AE
(dizziness) considered by the investigator to be related to the
study drug. The AE occurred approximately 15 min after
dosing, resolved within 20min and no actionwas taken. There
were no drug-related AEs in the healthy subject group.
Discussion
DTG is primarily eliminated through metabolism, and renal
elimination of unchanged drug represents less than 1 % of the
total dose administered. A study using a radio-labeled drug
demonstrated that approximately 30 % of the total oral dose is
excreted in the urine, the majority of which is represented by a
glucuronidated metabolite with a small percentage of oxida-
tive and other minor metabolites [8]. Approximately 65 % of
the total oral dose is recovered in the feces, represented mainly
by parent drug (53 % of total dose) [8]. Given this metabolism
and excretion profile, renal impairment would be expected to
have a minor effect on DTG PK.
The results of this study showed that the mean total DTG
plasma Cmax and AUC(0-∞) were 23–40% lower in subjects























Fig. 1 Mean plasma DTG and DTG-Gluc concentration-time plots in
subjects with and without renal impairment
Table 2 Comparison and summary of dolutegravir pharmacokinetic parameters and unbound concentrations
Parameter Renally impaired
(dolutegravir 50 mg, n =8)a
Healthy (dolutegravir
50 mg, n =8)a
Renally impaired vs. healthy,
GLS mean ratio (90 % CI)
Cmax, μg/mL 1.50 (34) 1.86 (45) 0.774 (0.532, 1.13)
AUC(0-∞), μg h/mL 23.5 (48) 37.1 (58) 0.601 (0.370, 0.975)
CL/F, L/hr 2.12 (48) 1.35 (58) 1.67 (1.03, 2.70)
Vz/F, L 38.8 (43) 29.9 (44) 1.36 (0.918, 2.02)
t1/2, h 12.7 (31) 15.4 (15) 0.818 (0.639, 1.05)
tmax, h 2.00 (1.0–3.0) 2.00 (1.0–4.0) NA
Unbound dolutegravir concentration at 3 h (μg/mL) 0.0122 (21) 0.0144 (53) 0.857 (0.587, 1.25)
Unbound dolutegravir concentration at 24 h (μg/mL) 0.0033 (45) 0.0062 (62) 0.510 (0.306, 0.851)
Unbound fraction at 3 h, % 0.86 (29) 0.86 (5) 1.05 (0.915, 1.21)
Unbound fraction at 24 h, % 1.04 (30) 1.11 (9) 0.957 (0.801, 1.14)
AUC(0-∞) area under the plasma concentration–time curve from time zero to infinity, CI confidence interval, CL/F apparent oral clearance, Cmax
maximum observed plasma concentration,GLS geometric least squares, NA not applicable, t1/2 half-life, tmax time to Cmax, Vz/F apparent volume of
distribution
a Data are geometric mean (coefficient of variation, %), except for tmax which is denoted as median (range)
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healthy subjects. However, there was considerable overlap in
DTG PK parameters between the groups. Median tmax values
were similar between the two subject populations, as were the
values for fraction unbound in plasma at 3 and 24 h post-dose.
Mean half-life was modestly shorter in the renally impaired
(12.7 h) group compared to the healthy controls (15.4 h).
There was no correlation between creatinine clearance and
DTG exposure. It has been well described that renal impair-
ment can lead to a number of changes that may affect the
pharmacokinetics of non-renally cleared drugs, including de-
creased hepatic and intestinal CYP activity, decreased intesti-
nal Pgp and MRP2 activity, and decreased or minimal impact
on hepatic OATP activity [12–15]. However, these previously
described effects on drug-metabolizing enzymes and trans-
porters would result in a higher exposure in the renal impair-
ment group, in contrast to the overall lower exposure seen in
this study.
Previous studies have demonstrated reduced exposure of
acidic drugs such as phenytoin in subjects with severe renal
impairment with an accompanied higher free fraction in plas-
ma and no significant change in the unbound exposure [16]. A
possible explanation for the findings in the current study is a
reduction in absorption. Patients with severe renal impairment
may have alterations in gastrointestinal transit time or bacterial
overgrowth in the gastrointestinal tract that may affect drug
absorption [17, 18]. There is evidence that DTG undergoes
enterohepatic recirculation [8] and gastrointestinal changes in
these subjects may impair this mechanism and contribute to
lower exposure in some patients.
The calculated free fraction was similar between renally
impaired and normal subjects, which may be explained by the
similar albumin levels between the two groups with no change
in the association constant. Therefore, the reduction in un-
bound DTG plasma concentration is driven by the reduction in
total DTG plasma concentration, not free fraction. The free
fraction (fu) observed in the healthy matched subjects in this
study is higher than that observed in a previous study in
healthy subjects [19]. The reason for this difference is unclear,
but a potential contributor is the slightly lower albumin con-
centration noted for the healthy subjects in this study resulting
in higher free fractions.
Although DTG-Gluc concentrations are much lower than
the total DTG concentrations, the plasma exposure of DTG-
Gluc in renally impaired subjects was 3 times (for Cmax) and
4 times (for AUC) higher than in normal subjects. However,
the half-life of DTG glucuronide was similar between the two
groups and similar to the DTG half-life, indicating formation
rate-limited kinetics for the glucuronide metabolite was not
altered by severe renal impairment. This suggests that the
glucuronide would not be expected to accumulate differen-
tially in renally impaired subjects compared to those with
normal function on repeat dosing. From a clinical standpoint,
the DTG-Gluc metabolite has no antiviral activity and would
not contribute to efficacy in the HIV-infected population.
Glucuronidation of DTG disrupts the key metal binding motif
of the compound and completely abrogates any antiviral ac-
tivity resulting from the active site binding to the integrase
enzyme. The increased DTG-Gluc concentrations in the
renally-impaired population would also not be expected to
be a safety concern as the glucuronide is still <10 % of the
exposure of parent DTG based on molar ratios. As such, the
glucuronide would not be considered for safety assessment
studies according to regulatory guidance on safety testing for
metabolites [20]. In addition, the glucuronide is a Phase II
metabolite; these metabolites are considered generally more
water soluble and less pharmacologically active, and do not
require testing [20].
The moderate effect of severe renal impairment in reducing
DTG Cmax and AUC by approximately 23–40 % is not
considered clinically significant. The reduction is less than
Table 3 Comparison of DTG-glucuronide pharmacokinetic parameters and evaluation of DTG-glucuronide/DTG parameter ratios
DTG-glucuronide parameter Renally impaired (dolutegravir 50 mg, n=8)a Healthy (dolutegravir 50 mg, n =8)a Renally impaired vs. healthy,
GLS mean ratio (90 % CI)
AUC(0-∞), μg.h/mL 2.48 (78) 0.54 (98) 4.30 (2.11, 8.76)
AUC(0-t), μg.h/mL 2.40 (79) 0.49 (107) 4.53 (2.16, 9.49)
Cmax, μg/mL 0.12 (68) 0.04 (83) 3.07 (1.60, 5.89)
t1/2, h 12.9 (30) 13.0 (31) 0.989 (0.724, 1.35)
tmax, h 3.00 (1.0, 8.0) 1.52 (1.0, 6.0) NA
DTG-Gluc/DTG
parameter ratio
Renally impaired (dolutegravir 50 mg, n =8)b Healthy (dolutegravir 50 mg, n =8)b Renally impaired vs. healthy,
estimate of difference (90 % CI)
AUC(0-t) ratio 0.053 (0.041, 0.385) 0.011 (0.004, 0.020) 0.040 (0.030, 0.140)
Cmax ratio 0.045 (0.033, 0.203) 0.015 (0.007, 0.023) 0.030 (0.020, 0.070)
t1/2 ratio 1.02 (0.930, 1.132) 0.836 (0.656, 1.144) 0.185 (−0.020, 0.320)
a Data denote geometric mean (CV%), except for tmax which is denoted as median (range)
b Data for DTG-Gluc/DTG parameter molar ratios are denoted as median (range). Hodges–Lehmann estimates for difference in ratios and 90 %
confidence interval are provided
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the 75 % reduction in DTG exposure between the 50 mg and
10 mg once-daily doses observed in a dose-ranging study of
DTG in treatment-naïve subjects (SPRING-1) [21]. This trial
demonstrated that all DTG doses (10, 25, and 50 mg) com-
bined with a 2 drug nucleoside reverse transcriptase inhibitor
backbone were equally efficacious and showed comparable
safety. This suggests that the decrease in DTG exposure ob-
served in the current study (approximately 40 %) would not be
clinically relevant in contemporary HIV treatment regimens.
Further support for this conclusion is provided by results from
co-administration of DTGwith darunavir/ritonavir (DRV/r). In
a Phase 1 study, DRV/r reduced DTG trough concentration by
38 % [22]. However, in the Phase 3 SAILING study of
treatment-experienced but INI-naive subjects, those subjects
taking DTG and DRV/r (accounting for ∼40 % subjects en-
rolled) showed equivalent virologic response to the remainder
of the DTG-treated population, despite lower exposure [3].
Therefore, it is unlikely that the decrease in exposure seen in
this study of subjects with severe renal impairment would have
a deleterious effect on virologic response.
This study indicates that no dose adjustment is needed in INI-
naïve subjects with severe renal impairment (CLcr of < 30 mL/
min, not on renal replacement therapy) and therefore also ex-
tends to those with mild and moderate impairment. However,
caution should be given to subjects with severe renal impairment
and who require higher exposures, such as those with resistance
to raltegravir. Furthermore, since metabolic inducers such as
efavirenz and tipranavir/ritonavir can decrease DTG concentra-
tions, alternative antiretroviral regimens without such drugs
should be considered in subjects with severe renal impairment
receiving DTG. Dose recommendations for DTG in end-stage
renal disease patients receiving any form of renal replacement
therapy cannot be given at the current time, although it is
unlikely that such therapy would have a significant effect on
DTG PK given the very high protein binding of >99 %.
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